Retacrit (epoetin zeta) is an effective treatment for chemotherapy-induced anaemiaThis research is explanatory study at company of manufactur which is listing in BEI with title 鈥淚nfluence of Performance Company鈥檚 Finance to Fluctuation Price Share Company of Manufacture Which Is Listing in BEI鈥...
Hospira has been authorised to market epoetin zeta [Retacrit] in the EU for the treatment of anaemiadoi:10.1186/1532-429X-16-S1-P300Training SupportHospital DepartmentsEducation Department, HospitalCrossref Hum Resour Manage. 1981 Nov-Dec;11(6):5-6.Weiner WH...
INN Epoetin alfa Epoetin alfa Epoetin zeta EC approval date Jun 1989 Aug 2007 Dec 2007 FDA approval Feb 1999 (Epogen®/Procrit®) – May 2018 (Retacrit®) Abbreviations: EC, European Commission; FDA, U.S. Food and Drug Administration; INN, International Nonproprietary Name. This review ...
Two patients with thalassemia minor and end-stage renal failure on hemodialysis were treated with epoetin zeta (Silapo, Retacrit; STADA, Germany), a medicinal product that was developed and registered as biosimilar to epoetin alfa. Dosing was titrated individually for two patients to achieve a ...
The PASCO II study (post-authorization safety cohort observation of Retacrit and Silapo (epoetin-味) administered subcutaneously for the treatment of renal anemia) followed 6,346 patients (4,501 Retacrit (group R); 1,845 Silapo (group S)) for up to 3 years of subcutaneous treatment with ...
Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utilitybiosimilar, chronic kidney disease, epoetin alfa, erythropoiesis, renal anemia, Retacrit®Mary Lynn Davis-Ajami,1 Jun Wu,2 Katherine Downton,3 Emilie Ludeman,3 Virginia Noxon...
(epoetin alpha) and Retacrit (epoetin zeta), were compared using (1) high performance size exclusion chromatography, (2) ELISA, (3) SDS-PAGE, (4) capillary zone electrophoresis and (5) in-vivo potency.Tested EPO products differed in content, isoform composition, and potency.Of the tested ...
Biosimilar epoetin zeta: extrapolation of indications and real world utilization experienceBiosimilarsRetacritepoetinextrapolationpost-marketing surveillanceEPARIntroduction: There is an essential need for clinicians to understand the development and approval process of biosimilars. Extrapolation of efficacy and ...
Retacrit®Epoetin zeta was granted marketing authorization in October 2007 by the European Medicines Agency as a recombinant human erythropoietin erythropoiesis-stimulating agent to treat symptomatic anemia of renal origin in adult and pediatric patients on hemodialysis and adults on peritoneal d...